Ovid Therapeutics (OVID)

• Market cap: $86M
• 1 day: 6.14%
• 5 days: 27.37%
• 1 month: 129.38%
• 3 months: 315.24%
• 6 months: 125.03%
• Year to date: 26.30%
• 1 year: -6.92%
• 5 years: -80.03%
• 10 years: -90.12%
• Sector: Healthcare
• Industry: Biotechnology

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Employees: 23

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

15.03% less ownership

Funds ownership: 65.28% [Q1] → 50.25% (-15.03%) [Q2]

16% less funds holding

Funds holding: 82 [Q1] → 69 (-13) [Q2]

19% less capital invested

Capital invested by funds: $14.5M [Q1] → $11.8M (-$2.68M) [Q2]

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

39% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 28

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1.50 24% upside
• Avg. target: $1.50 24% upside
• High target: $1.50 24% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju

24% upside $1.50

Buy Maintained

27 May 2025